Craniopharyngioma is a rare, slow-growing brain tumor that develops near the pituitary gland—a tiny but vital structure at the base of the brain that controls many essential bodily functions through hormone production. Although the tumor itself is not cancerous, its location can lead to serious health challenges, affecting vision, hormone balance, and overall quality of life. Treatment focuses on carefully removing or controlling the tumor while preserving important brain structures, which requires a thoughtful combination of surgery, radiation, and ongoing medical care.

What Drives Treatment for Craniopharyngioma

When someone is diagnosed with craniopharyngioma, the main goals of treatment center around controlling the tumor’s growth, relieving symptoms, and protecting nearby brain structures that manage crucial functions. Because this tumor forms close to the pituitary gland—which produces hormones that regulate growth, metabolism, reproduction, and stress responses—and the hypothalamus—which helps regulate body temperature, hunger, thirst, and sleep—even a small tumor can have wide-ranging effects.^[1]

Treatment strategies depend heavily on several factors: the size and exact location of the tumor, the patient’s age, and whether this is a first diagnosis or a tumor that has returned. In children, additional considerations include protecting growth and development, while in adults, preserving vision and hormone function often takes priority. Medical societies around the world have established treatment guidelines, but because craniopharyngioma is so rare—affecting only about 2 people per million each year—doctors often tailor approaches to each individual’s unique situation.^[2]

There are two main types of craniopharyngioma: adamantinomatous, which can occur at any age but is most common in children aged 5 to 14, and papillary, which almost exclusively affects adults aged 50 to 74. This distinction matters because these types behave differently and may respond to different treatments.^[2][3]

Despite being classified as benign (noncancerous), craniopharyngiomas are treated as serious, chronic conditions. More than 90% of people with this tumor are alive five years after diagnosis, but about half of all tumors return even after successful treatment. This means many patients require lifelong monitoring and may need additional treatments over time.^[2]

Standard Treatment Approaches

Surgery as the Primary Treatment

Surgery represents the cornerstone of craniopharyngioma treatment. When doctors can safely do so, they aim to remove the entire tumor, which is called a gross total resection. This approach offers the best chance of long-term tumor control. However, complete removal is not always possible or advisable because craniopharyngiomas often grow in tight spaces, wrapping around or pressing against delicate structures like the optic nerves (which carry visual signals from the eyes to the brain), blood vessels, and the hypothalamus.^[13]

Two main surgical approaches are used. The first is called an open craniotomy, where surgeons create an opening in the skull to access the tumor directly. The second, increasingly popular option is minimally invasive transsphenoidal surgery, also known as endoscopic surgery. In this technique, surgeons insert special instruments and a tiny camera through the nose and sinuses to reach the tumor at the base of the skull. This approach avoids any incisions on the face or scalp and can lead to faster recovery with less discomfort. The choice between these methods depends on the tumor’s size, shape, and exact location.^[13][11]

When complete removal would risk damaging vital brain structures, surgeons perform a subtotal resection, removing as much tumor as safely possible while leaving small amounts behind. This more conservative approach helps preserve important functions like vision, hormone production, memory, and emotional regulation. Studies have shown that subtotal resection followed by radiation therapy can achieve tumor control rates similar to those of complete removal, but with potentially fewer complications affecting quality of life.^[9]

The most common side effects after craniopharyngioma surgery relate to hormone imbalances. Many patients develop panhypopituitarism, meaning the pituitary gland stops producing one or more hormones. This can lead to growth hormone deficiency (affecting children’s growth and adults’ energy levels and bone health), thyroid hormone deficiency (causing fatigue and weight changes), adrenal insufficiency (leading to weakness and low blood pressure), and reproductive hormone deficiencies (affecting puberty in children or menstrual cycles in women). Another frequent complication is diabetes insipidus, a condition where the body cannot regulate fluid balance properly, leading to excessive thirst and urination.^[2][8]

Vision problems are common before surgery, and while many patients experience improvement after the tumor is removed, some degree of visual loss may persist. If the tumor has pressed on the optic nerves or optic chiasm (where the optic nerves cross) for a long time, the damage may not be fully reversible.^[1]

Radiation Therapy for Tumor Control

Radiation therapy plays a crucial role in craniopharyngioma treatment, particularly when surgery cannot remove the entire tumor. It uses carefully aimed high-energy beams to damage tumor cells and prevent them from growing. Doctors typically recommend radiation when imaging scans show that some tumor remains after surgery, or when a tumor that was previously treated begins growing again.^[13]

Several types of radiation therapy are used. Conventional external beam radiation delivers treatment in small daily doses over several weeks, allowing healthy tissue time to recover between sessions. More precise techniques include stereotactic radiotherapy and radiosurgery, which focus intense radiation beams on the tumor from multiple angles, minimizing exposure to surrounding healthy brain tissue. For very small tumors or tumor remnants, a single high-dose treatment called radiosurgery may be appropriate. For larger tumors, fractionated stereotactic radiotherapy—given in multiple smaller doses—is often preferred.^[7][11]

Some specialized centers offer proton beam therapy, a cutting-edge form of radiation that uses protons instead of traditional X-rays. Protons can deliver their energy more precisely to the tumor while sparing more of the surrounding brain tissue. This technology may be particularly valuable for treating children, whose developing brains are especially vulnerable to radiation effects, though access to proton beam centers remains limited.^[7]

Radiation therapy is generally well-tolerated but can cause side effects. In the short term, patients may experience fatigue, hair loss in the treated area, and scalp irritation. Long-term effects can include further hormone deficiencies (even if the pituitary was functioning after surgery), vision changes if the optic nerves receive radiation, and in rare cases, cognitive changes. In children, radiation may affect learning abilities and development, which is why doctors carefully weigh the benefits against these risks, sometimes delaying radiation in very young children if possible.^[12]

Hormone Replacement Therapy

Because most patients with craniopharyngioma develop hormone deficiencies either from the tumor itself or as a result of treatment, hormone replacement therapy becomes a long-term aspect of care. An endocrinologist—a doctor who specializes in hormone disorders—works closely with the treatment team to manage these issues.^[5]

Patients may need to take several different hormone medications. Growth hormone replacement is important for children to support normal development and for adults to maintain bone density, muscle mass, and energy levels. Thyroid hormone replacement (levothyroxine) addresses thyroid deficiency, helping regulate metabolism and energy. Cortisol replacement (hydrocortisone or similar medications) is essential for patients with adrenal insufficiency, as cortisol helps the body respond to stress and illness. Sex hormone replacement may include testosterone for men or estrogen and progesterone for women to support reproductive health and bone strength.^[2]

For diabetes insipidus, patients take desmopressin, a medication that replaces the missing hormone that helps kidneys concentrate urine and maintain fluid balance. This medication can be taken as a tablet, nasal spray, or injection.^[8]

Finding the right hormone doses requires careful monitoring through regular blood tests and clinical assessments. Doses often need adjustment over time, especially in growing children or during periods of stress or illness. Patients work closely with their endocrinologist, sometimes for the rest of their lives, to ensure optimal hormone replacement.

Treatment in Clinical Trials

Targeted Therapy with BRAF Inhibitors

One of the most exciting recent developments in craniopharyngioma treatment involves drugs that target specific genetic changes in tumor cells. Researchers discovered that many papillary craniopharyngiomas—the type that occurs almost exclusively in adults—contain a specific mutation in a gene called BRAF. This mutation, designated BRAF V600E, causes cells to grow uncontrollably by activating a cellular signaling pathway involved in cell division.^[10][20]

Scientists realized that drugs already approved for treating melanoma (a type of skin cancer) and other cancers with the same BRAF mutation might work for craniopharyngioma. A groundbreaking clinical trial tested the combination of two targeted therapy drugs: vemurafenib (brand name Zelboraf) and cobimetinib (brand name Cotellic). Vemurafenib blocks the abnormal BRAF protein directly, while cobimetinib blocks another protein called MEK that works downstream in the same signaling pathway. Using both drugs together creates a more complete blockade of this growth pathway.^[10]

The trial results, published in the New England Journal of Medicine in 2023, showed remarkable success. Of the 16 participants with papillary craniopharyngioma containing the BRAF mutation, 15 experienced significant tumor shrinkage. Some tumors shrank so dramatically that about half of the participants chose not to have additional surgery or radiation after completing the drug treatment. The tumors continued responding to treatment for a median of 22 months, and many patients experienced improvement in their symptoms.^[10][20]

This was a Phase II clinical trial, which means it focused on determining whether the treatment is effective and at what dose. Phase I trials test safety and dosing in small groups, Phase II trials evaluate effectiveness in larger groups, and Phase III trials compare new treatments to standard treatments in even larger populations. Although the vemurafenib and cobimetinib combination hasn’t yet received formal FDA approval specifically for craniopharyngioma, many doctors have already begun using it based on these trial results—a practice called “off-label” use.^[20]

Side effects from these targeted therapies can include joint pain, fatigue, skin rashes, sensitivity to sunlight, nausea, and diarrhea. Some patients develop elevated liver enzymes or changes in heart rhythm that require monitoring. However, many patients in the trial found these side effects manageable compared to the risks of surgery or radiation. The long-term side effects of extended treatment with these drugs for craniopharyngioma are still being studied.^[10]

Not all craniopharyngiomas have this BRAF mutation—it’s found primarily in the papillary type, not in adamantinomatous craniopharyngiomas. Therefore, testing the tumor tissue for this genetic change is essential before considering this treatment. This testing can be done on biopsy samples or on tissue removed during surgery.^[20]

Understanding the Biology of Different Tumor Types

Research into the molecular biology of craniopharyngiomas has revealed fundamental differences between the two types. Adamantinomatous craniopharyngiomas typically have mutations in a gene called CTNNB1, which produces a protein called beta-catenin. This protein plays a role in a cellular signaling pathway called the WNT pathway, which helps control cell growth and development. When beta-catenin accumulates abnormally in cells, it can drive uncontrolled cell division and tumor formation.^[9]

Understanding these molecular differences is helping researchers develop more targeted approaches for adamantinomatous tumors as well. Scientists are investigating drugs that might block the WNT/beta-catenin pathway, though these therapies are still in earlier stages of development compared to the BRAF inhibitors.

Chemotherapy Approaches

Traditional chemotherapy—drugs that kill rapidly dividing cells throughout the body—has generally not been effective for craniopharyngiomas. These tumors grow very slowly, and chemotherapy works best against fast-growing tumors. However, chemotherapy has emerged as an option specifically for certain papillary craniopharyngiomas with BRAF mutations, particularly when combined with targeted therapies.^[2]

For cystic craniopharyngiomas (tumors with fluid-filled spaces), doctors sometimes inject chemotherapy drugs directly into the cyst. Medications like bleomycin or interferon-alpha have been used this way in some centers, particularly in Europe. The drug is injected into the cyst during a minor procedure, where it works locally to prevent the cyst from refilling. This approach can delay the need for major surgery or radiation, especially in children or in cases where previous treatments have failed. However, this technique is not widely available and remains somewhat experimental.^[12]

Novel Radiation Techniques in Clinical Studies

Researchers continue refining radiation therapy techniques to make them even more precise and less damaging to healthy tissue. Clinical trials are evaluating advanced forms of intensity-modulated radiation therapy (IMRT) and proton beam therapy to determine optimal doses and treatment schedules that maximize tumor control while minimizing side effects, particularly in children.^[12]

Some trials are also investigating the best timing for radiation therapy—whether it’s better to give it immediately after incomplete tumor removal or to wait and monitor with imaging scans, using radiation only if the tumor shows signs of growing back. This “watch and wait” approach, combined with ready intervention if needed, might spare some patients from radiation entirely or at least delay it until they’re older.

International Trial Availability

Clinical trials for craniopharyngioma are conducted at specialized medical centers around the world, including in the United States, Europe, and other regions. Major cancer centers and academic medical institutions typically lead these studies. Patients interested in participating in clinical trials can search databases like ClinicalTrials.gov (for U.S. and international trials) or speak with their treatment team about available options. Because craniopharyngioma is so rare, some trials accept patients from multiple countries or states, though travel to the study site is usually required.^[20]

Most common treatment methods

• Surgical removal
  • Gross total resection when safely possible, aiming to remove the entire tumor
  • Subtotal resection when complete removal would risk damaging vital brain structures like the hypothalamus, pituitary gland, or optic nerves
  • Open craniotomy approach through an opening in the skull
  • Minimally invasive transsphenoidal/endoscopic approach through the nose and sinuses, avoiding external incisions
• Radiation therapy
  • Conventional external beam radiation delivered in daily fractions over several weeks
  • Stereotactic radiotherapy using precise, focused beams from multiple angles to minimize damage to healthy tissue
  • Radiosurgery delivering a single high-dose treatment for small tumors or remnants
  • Proton beam therapy using protons instead of X-rays for more precise energy delivery, particularly beneficial for children
  • Used after incomplete surgical removal or for recurrent tumors
• Targeted therapy
  • Combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) for papillary craniopharyngiomas with BRAF V600E mutation
  • Blocks specific cellular signaling pathways driving tumor growth
  • Can substantially shrink tumors, potentially delaying or eliminating need for surgery or radiation
  • Requires genetic testing to identify appropriate candidates
• Hormone replacement therapy
  • Growth hormone replacement for children and adults with growth hormone deficiency
  • Thyroid hormone replacement (levothyroxine) for thyroid deficiency
  • Cortisol replacement (hydrocortisone) for adrenal insufficiency
  • Sex hormone replacement (testosterone, estrogen, progesterone) for reproductive hormone deficiencies
  • Desmopressin for diabetes insipidus to help regulate fluid balance
  • Lifelong management with regular monitoring and dose adjustments
• Intracystic therapy
  • Direct injection of medications like bleomycin or interferon-alpha into cystic portions of tumor
  • Can delay need for major surgery or radiation
  • Particularly used for recurrent cystic tumors
  • Available at specialized centers, remains somewhat experimental

Follow-Up Care and Monitoring

Because craniopharyngiomas have a high recurrence rate—about half return over time—regular follow-up is essential throughout a patient’s life. Follow-up typically includes appointments every six to twelve months, though the frequency may vary based on individual circumstances. During these visits, doctors perform neurological examinations, assess vision, and review hormone levels through blood tests.^[7]

Magnetic resonance imaging (MRI) scans are the primary tool for monitoring tumor status. These scans create detailed images of the brain using magnetic fields and radio waves, allowing doctors to detect any tumor regrowth early, when it may be easier to treat. The frequency of MRI scans typically decreases over time if no recurrence is detected, but patients may need periodic imaging indefinitely.^[13]

Eye examinations are another important component of follow-up care. An ophthalmologist or neuro-ophthalmologist performs detailed vision testing to monitor for any changes that might indicate tumor recurrence or delayed effects of treatment. These assessments include not just reading chart tests but also specialized tests of peripheral vision and the appearance of the optic nerves.^[7]

Managing the long-term effects of treatment requires a multidisciplinary team. In addition to the neurosurgeon, radiation oncologist, and endocrinologist, patients may work with neuropsychologists to address cognitive or emotional changes, dietitians to manage weight and nutrition issues (which can be significant, especially in patients with hypothalamic damage), and physical therapists or rehabilitation specialists if needed.^[3]

Quality of Life Considerations

While survival rates for craniopharyngioma are high, quality of life can be significantly affected. The tumor’s location near the hypothalamus means that even successful treatment can lead to challenges with weight regulation, sleep, mood, memory, and behavior. Many patients, especially children, struggle with obesity after treatment because hypothalamic injury can disrupt normal appetite regulation and metabolism. This isn’t simply a matter of overeating; the brain’s mechanisms for signaling fullness and regulating energy balance may be permanently altered.^[14]

Children may experience learning difficulties, slower academic progress, and social challenges. Adults may face fatigue, depression, anxiety, or changes in personality and behavior. These changes can be subtle or profound, and they often require as much attention as the physical aspects of treatment. Psychological support, counseling, and support groups can be invaluable resources for patients and families navigating these challenges.^[12]

Many medical centers now recognize that the goal of treatment isn’t just removing the tumor but preserving the patient’s ability to live independently and maintain social functioning. This has led some treatment teams to favor more conservative surgical approaches combined with radiation, accepting a slightly higher risk of recurrence in exchange for better preservation of quality of life. There’s no single “right” answer—each patient and family must work with their medical team to determine what balance makes the most sense for their particular situation.^[9]